Insmed (NASDAQ:INSM) Reaches New 12-Month High on Analyst Upgrade

Shares of Insmed, Inc. (NASDAQ:INSM) hit a new 52-week high on Monday after Guggenheim raised their price target on the stock from $125.00 to $172.00. Guggenheim currently has a buy rating on the stock. Insmed traded as high as $146.91 and last traded at $145.86, with a volume of 288114 shares changing hands. The stock had previously closed at $145.10.

INSM has been the subject of several other reports. William Blair started coverage on shares of Insmed in a report on Wednesday, August 20th. They set an “outperform” rating for the company. Stifel Nicolaus lifted their price objective on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, August 14th. Jefferies Financial Group lifted their price target on Insmed from $129.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. Morgan Stanley lifted their price target on Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Finally, Wells Fargo & Company boosted their price objective on Insmed from $140.00 to $171.00 and gave the company an “overweight” rating in a research report on Wednesday, September 3rd. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and a consensus price target of $139.86.

Insider Activity at Insmed

In other news, insider Michael Alexander Smith sold 24,272 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the sale, the insider directly owned 54,902 shares in the company, valued at $7,899,848.78. This represents a 30.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Sara Bonstein sold 58,400 shares of the company’s stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the sale, the chief financial officer owned 73,505 shares of the company’s stock, valued at $7,546,758.35. This trade represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 378,382 shares of company stock worth $40,169,038 in the last 90 days. 3.00% of the stock is owned by insiders.

Institutional Trading of Insmed

Several large investors have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. grew its holdings in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 221 shares in the last quarter. Elequin Capital LP purchased a new stake in shares of Insmed in the fourth quarter valued at about $28,000. ORG Partners LLC grew its holdings in shares of Insmed by 220.2% in the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank purchased a new stake in shares of Insmed in the second quarter valued at about $28,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Insmed in the second quarter valued at about $33,000.

Insmed Stock Performance

The firm’s 50 day moving average price is $116.55 and its two-hundred day moving average price is $90.60. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The firm has a market cap of $31.12 billion, a PE ratio of -25.78 and a beta of 0.97.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The firm had revenue of $107.42 million during the quarter, compared to analysts’ expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business’s quarterly revenue was up 18.9% on a year-over-year basis. During the same period last year, the company earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. On average, research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.